Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11118062rdf:typepubmed:Citationlld:pubmed
pubmed-article:11118062lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:11118062lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:11118062lifeskim:mentionsumls-concept:C1514559lld:lifeskim
pubmed-article:11118062lifeskim:mentionsumls-concept:C0009221lld:lifeskim
pubmed-article:11118062lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:11118062lifeskim:mentionsumls-concept:C0220898lld:lifeskim
pubmed-article:11118062lifeskim:mentionsumls-concept:C0033713lld:lifeskim
pubmed-article:11118062lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:11118062lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:11118062lifeskim:mentionsumls-concept:C1515979lld:lifeskim
pubmed-article:11118062pubmed:issue23lld:pubmed
pubmed-article:11118062pubmed:dateCreated2000-12-12lld:pubmed
pubmed-article:11118062pubmed:abstractTextThe position of the point mutation in the c-K-ras gene appears associated with different degrees of aggressiveness in human colorectal tumors. In addition, colon tumors carrying K-ras codon 12 mutations associate with lower levels of apoptosis than tumors lacking this mutation. To test the hypothesis of a distinct transforming capacity of different K-ras forms in an in vitro system, we generated stable transfectants of NIH3T3 cells expressing a plasmid containing K-ras mutated at codon 12 (K12) or at codon 13 (K13), or overexpressing the K-ras proto-oncogene (Kwt-oe). We evaluated changes in morphology, proliferative capacity, contact inhibition, and predisposition to apoptosis and anchorage-independent growth in K12, K13, and Kwt-oe transformants. In addition, we studied alterations in expression and/or activation of proteins that participate in signal transduction downstream of Ras or are involved in the regulation of apoptosis and cell-cell (E-cadherin and beta-catenin) and cell-substrate (focal adhesion kinase) interactions. We observed that K13 or Kwt-oe transformants died synchronically 24-48 h after reaching confluency. Their death was apoptotic. In contrast, K12 grew, forming bigger colonies with higher cell densities; and before reaching confluency, spontaneously formed spheroids and showed no sign of apoptosis. The enhanced resistance to apoptosis, loss of contact inhibition, and predisposition to anchorage-independent growth in the K12 transformants were associated with higher AKT/protein kinase B activation, bcl-2, E-cadherin, beta-catenin, and focal adhesion kinase overexpression, and RhoA underexpression, whereas the increased sensitivity of K13 or Kwt-oe transformants to apoptosis was associated with increased activation of the c-Jun-NH2-terminal kinase 1 pathway. All transformants showed a similar overactivation of mitogen-activated protein kinases and levels of bax expression similar to the endogenous level. Therefore, in our in vitro model, the localization of the mutation in the K-ras gene predisposes to a different level of aggressiveness in the transforming phenotype. K12 may increase aggressiveness not by altering proliferative pathways, but by the differential regulation of K-Ras downstream pathways that lead to inhibition of apoptosis, enhanced loss of contact inhibition, and increased predisposition to anchorage-independent growth. These results offer a molecular explanation for the increased aggressiveness of the tumors with K-ras codon 12 mutations observed in the clinical setting.lld:pubmed
pubmed-article:11118062pubmed:languageenglld:pubmed
pubmed-article:11118062pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:citationSubsetIMlld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11118062pubmed:statusMEDLINElld:pubmed
pubmed-article:11118062pubmed:monthDeclld:pubmed
pubmed-article:11118062pubmed:issn0008-5472lld:pubmed
pubmed-article:11118062pubmed:authorpubmed-author:GuerreroSSlld:pubmed
pubmed-article:11118062pubmed:authorpubmed-author:ManguesRRlld:pubmed
pubmed-article:11118062pubmed:authorpubmed-author:MazoAAlld:pubmed
pubmed-article:11118062pubmed:authorpubmed-author:CasanovaIIlld:pubmed
pubmed-article:11118062pubmed:authorpubmed-author:FarréLLlld:pubmed
pubmed-article:11118062pubmed:authorpubmed-author:CapellàGGlld:pubmed
pubmed-article:11118062pubmed:issnTypePrintlld:pubmed
pubmed-article:11118062pubmed:day1lld:pubmed
pubmed-article:11118062pubmed:volume60lld:pubmed
pubmed-article:11118062pubmed:ownerNLMlld:pubmed
pubmed-article:11118062pubmed:authorsCompleteYlld:pubmed
pubmed-article:11118062pubmed:pagination6750-6lld:pubmed
pubmed-article:11118062pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:meshHeadingpubmed-meshheading:11118062...lld:pubmed
pubmed-article:11118062pubmed:year2000lld:pubmed
pubmed-article:11118062pubmed:articleTitleK-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.lld:pubmed
pubmed-article:11118062pubmed:affiliationLaboratori d'Investigació Gastrointestinal, Institut de Recerca, Hospital de Sant Pau, Barcelona, Spain.lld:pubmed
pubmed-article:11118062pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11118062pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11118062lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11118062lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11118062lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11118062lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11118062lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11118062lld:pubmed